Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

NXTC Relative to the S&P 500

NXTC Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the NextCure, Inc. (NASD:NXTC) seasonal charts above shows that a Buy Date of July 30 and a Sell Date of October 18 has resulted in a geometric average return of 6.85% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 3 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 60.91% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of NXTC, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

To download NXTC seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: NXTC